Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban alone versus enoxaparin followed by apixaban for prevention of post-thrombotic syndrome after proximal lower-extremity deep vein thrombosis
IRCT20250814066856N1Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Aug 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of apixaban and enoxaparin in deep vein thrombosis (DVT) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Post-thrombotic syndrome by Villalta score and Venous ulcer occurrence. Started Aug 2025; status: completed.
02
Drugs
apixabanenoxaparin
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on IRCT20250814066856N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250814066856N1.